Sublingual buprenorphine spray
US9839611B2 · kind B2 · utility
5Cited by
6References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 27, 2015 |
| Grant date | Dec 12, 2017 |
| Priority date | — |
| Expiry date | Oct 27, 2035 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides sublingual formulations containing buprenorphine, a pharmaceutically acceptable salt thereof, or a derivative thereof. The invention further provides sublingual formulations containing buprenorphine and naloxone, pharmaceutically acceptable salts thereof or derivatives thereof. The invention further provides a method of treating pain or opioid dependence by administering sublingual formulations containing buprenorphine, a pharmaceutically acceptable salt thereof, or a derivative thereof to a patient in need thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.